Placebo News and Research

RSS

DO-HEALTH study aims to provide evidence for strategies that prevent chronic disease in seniors

Europe's largest healthy ageing study - DO-HEALTH - which aims to provide evidence for the safety of three simple preventive interventions: vitamin D, omega-3 fatty acids and a simple home exercise programme, has recruited 532 of its target 2,000 seniors.

10 Sep 2013

Trial to compare e-cigarettes with nicotine patches shows success in helping smokers to quit

First trial to compare e-cigarettes with nicotine patches shows comparable success in helping smokers to quit.

10 Sep 2013

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.

9 Sep 2013

D&A PHARMA to present 3 clinical studies for ALCOVER in 14th Congress of ESBRA at Warsaw

D&A PHARMA, a leading company in the Addiction therapeutic area, announces today its strong participation in the 14th Congress of European Company of Biomedical Search on the Alcoholism (ESBRA), which will be held in Warsaw from September 8th to 11th.

7 Sep 2013

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.

7 Sep 2013

Experimental agent fails to increase HDL levels, reveals new study

The search continues for an agent that increases high-density lipoprotein (HDL) and reduces arterial plaque, after the experimental apolipoprotein A1 (apoA1) inducer, RVX-208 failed to do so in the ApoA1 Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation (ASSURE) study.

5 Sep 2013

Elan enrolls first patient dosing in phase 2a study of ELND005 in Down syndrome

Elan Corporation, plc (NYSE: ELN) announced today the first patient dosing in a Phase 2a study of ELND005 in Down syndrome. Study ELND005-DS201 will evaluate the safety and pharmacokinetics of 2 doses of ELND005 and placebo in young adults with Down syndrome without dementia, and will also include select cognitive and behavioural measures.

5 Sep 2013

Viewpoints: Economic theory shows health law's taxes will affect jobs; no indication that part-time jobs are increasing; doctors 'ditching' Medicare?

The Affordable Care Act was intended to expand the fraction of the United States population covered by health insurance. The law includes taxes on employers and various implicit taxes on employees that go into effect over the next two years.

5 Sep 2013

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States Food and Drug Administration has granted Priority Review status for the Biologics License Application for its new investigational drug vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis.

5 Sep 2013

Increased mortality in schizophrenia ‘not attributable to drug therapy’

The increased mortality risk observed among patients with severe psychiatric illness, including schizophrenia, does not seem to be attributable to use of psychopharmacologic therapy, study findings indicate.

4 Sep 2013

Endo, BDSI complete interim analyses of Phase III trials for BEMA Buprenorphine

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc., and BioDelivery Sciences International, Inc. announced today that the companies have completed interim analyses of both the opioid naive and opioid experienced Phase III trials for BEMA Buprenorphine.

4 Sep 2013

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Patients with coronary artery disease and low levels of "good cholesterol - or high-density lipoprotein - who were treated with a drug designed to increase HDL levels and reduce coronary plaque build-up, experienced no better results than those treated with placebo, according to research conducted by the Cleveland Clinic Coordinating Center for Clinical Research.

4 Sep 2013

Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or slowing in the progression of coronary atherosclerosis, according to a study published by JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology Congress 2013.

4 Sep 2013

Study: Fixed-dose combination medication helps CVD patients

In a randomized trial that included about 2,000 patients with or at high risk of cardiovascular disease (CVD), use of a fixed-dose combination medication for blood pressure, cholesterol, and platelet control compared to usual care resulted in significantly improved medication adherence after 15 months and small improvements in systolic blood pressure and low-density lipoprotein cholesterol, according to a study in the September 4 issue of JAMA.

4 Sep 2013

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

Patients with clogged and hardened arteries who already have their blood pressure under control may benefit from an additional blood pressure-lowering medication, according to research from the Cleveland Clinic Coordinating Center for Clinical Research (C5Research).

4 Sep 2013

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or "bad cholesterol").

4 Sep 2013

Renin inhibitor aliskiren not effective in slowing progression of coronary atherosclerosis

3 Sep 2013

Omecamtiv mecarbil fails to achieve primary endpoint in phase II ATOMIC-AHF study

Omecamtiv mecarbil, a cardiac myosin-activator, did not achieve its primary efficacy endpoint in reducing dyspnoea (shortness of breath) in patients with acute heart failure, according to the results of the phase II ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) study.

3 Sep 2013

Facebook groups are effective tool for increasing HIV testing among at-risk populations

Peer-led Facebook groups are an acceptable and effective tool for increasing home-based HIV testing among at-risk populations. HIV infection is a major health concern for men who have sex with men (MSM), especially among African Americans and Latinos who have high rates of incident cases and new diagnoses.

3 Sep 2013

Anti-diabetic drug alogliptin meets primary endpoint in EXAMINE trial

Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial presented at the European Society of Cardiology Congress.

2 Sep 2013

Placebo News and Research

DO-HEALTH study aims to provide evidence for strategies that prevent chronic disease in seniors

Trial to compare e-cigarettes with nicotine patches shows success in helping smokers to quit

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

D&A PHARMA to present 3 clinical studies for ALCOVER in 14th Congress of ESBRA at Warsaw

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

Experimental agent fails to increase HDL levels, reveals new study

Elan enrolls first patient dosing in phase 2a study of ELND005 in Down syndrome

Viewpoints: Economic theory shows health law's taxes will affect jobs; no indication that part-time jobs are increasing; doctors 'ditching' Medicare?

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

Increased mortality in schizophrenia ‘not attributable to drug therapy’

Endo, BDSI complete interim analyses of Phase III trials for BEMA Buprenorphine

RVX-208 drug fails to increase good cholesterol levels in ASSURE trial

Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

Study: Fixed-dose combination medication helps CVD patients

AQUARIUS trial data shows Aliskiren reduced incidents of death, stroke, heart attack

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Renin inhibitor aliskiren not effective in slowing progression of coronary atherosclerosis

Omecamtiv mecarbil fails to achieve primary endpoint in phase II ATOMIC-AHF study

Facebook groups are effective tool for increasing HIV testing among at-risk populations

Anti-diabetic drug alogliptin meets primary endpoint in EXAMINE trial

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News